Subscribe To
TPTX / TPTX Stock Soars 115% as Bristol Myers Announces Takeover of Turning Point Therapeutics
TPTX News
By InvestorPlace
June 3, 2022
TPTX Stock Soars 115% as Bristol Myers Announces Takeover of Turning Point Therapeutics
Turning Point Therapeutics (TPTX) stock is rocketing higher on Friday following news of a deal with Bristol-Myers Squibb (BMY). The post TPTX Stock S more_horizontal
By Pulse2
June 3, 2022
Why Bristol-Myers Squibb (BMY) Is Buying Turning Point Therapeutics (TPTX) In A $4.1 Billion Deal
Bristol Myers Squibb (NYSE: BMY) is buying Turning Point Therapeutics, Inc. (NASDAQ: TPTX) in a $4.1 billion deal. These are the details. more_horizontal
By Market Watch
June 3, 2022
Turning Point Therapeutics stock more than doubles after Bristol Myers buyout deal valuing company at $3.8 billion
Shares of Turning Point Therapeutics Inc. TPTX, +2.21% more than doubled, up 116.7%, in premarket trading Friday, after the clinical-stage oncology co more_horizontal
By MarketBeat
April 20, 2022
Is Turning Point Therapeutics Stock at a Turning Point?
The volatile stock of Turning Point Therapeutics (NASDAQ: TPTX) is once again piquing the interest of high risk traders after the company announced en more_horizontal
By Stockmarketcom
April 14, 2022
Best Biotech Stocks To Buy Now? 5 To Know
Check out these biotech stocks with exciting developments today. more_horizontal
By Zacks Investment Research
January 25, 2022
What Makes Turning Point Therapeutics (TPTX) a New Buy Stock
Turning Point Therapeutics (TPTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Ran more_horizontal
By Zacks Investment Research
January 25, 2022
What Makes Turning Point Therapeutics (TPTX) a New Buy Stock
Turning Point Therapeutics (TPTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Ran more_horizontal
By Zacks Investment Research
January 25, 2022
What Makes Turning Point Therapeutics (TPTX) a New Buy Stock
Turning Point Therapeutics (TPTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Ran more_horizontal